Deutsche Bank AG Has $104,000 Holdings in Inhibrx Biosciences, Inc. $INBX

Key Points

• Deutsche Bank AG significantly reduced its stake in Inhibrx Biosciences, selling 12,166 shares and lowering its ownership by 62% to 0.05% of the company's stock, valued at $104,000.
• Several institutional investors have recently acquired new stakes in Inhibrx, with notable investments from Wells Fargo & Company and MIRAE ASSET GLOBAL, each valued at around $102,000.
• Inhibrx Biosciences reported earnings of ($1.85) per share, which surpassed analysts' expectations, and the company currently has a consensus rating of "Hold" from equity analysts.

Deutsche Bank AG decreased its holdings in Inhibrx Biosciences, Inc. (NASDAQ:INBX - Free Report) by 62.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,443 shares of the company's stock after selling 12,166 shares during the period. Deutsche Bank AG owned about 0.05% of Inhibrx Biosciences worth $104,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in INBX. State of Wyoming acquired a new position in Inhibrx Biosciences in the 4th quarter valued at approximately $83,000. Wells Fargo & Company MN acquired a new stake in shares of Inhibrx Biosciences during the 4th quarter valued at $102,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Inhibrx Biosciences during the 4th quarter valued at $102,000. JPMorgan Chase & Co. increased its stake in shares of Inhibrx Biosciences by 47.8% in the fourth quarter. JPMorgan Chase & Co. now owns 7,592 shares of the company's stock worth $117,000 after acquiring an additional 2,457 shares during the last quarter. Finally, MetLife Investment Management LLC purchased a new stake in shares of Inhibrx Biosciences during the fourth quarter worth $118,000. 82.46% of the stock is owned by hedge funds and other institutional investors.

Inhibrx Biosciences Stock Down 0.3%

Inhibrx Biosciences stock traded down $0.08 during mid-day trading on Thursday, hitting $27.72. 72,797 shares of the company's stock were exchanged, compared to its average volume of 106,107. Inhibrx Biosciences, Inc. has a 1-year low of $10.81 and a 1-year high of $28.49. The stock has a 50 day moving average of $22.29 and a two-hundred day moving average of $16.26. The company has a current ratio of 4.98, a quick ratio of 4.98 and a debt-to-equity ratio of 1.45. The stock has a market cap of $401.52 million, a P/E ratio of -2.62 and a beta of 0.33.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($1.85) earnings per share for the quarter, topping analysts' consensus estimates of ($2.92) by $1.07. The company had revenue of $1.30 million during the quarter. As a group, analysts anticipate that Inhibrx Biosciences, Inc. will post 104.88 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on INBX. JMP Securities reissued a "market perform" rating on shares of Inhibrx Biosciences in a research report on Friday, August 22nd. Wall Street Zen upgraded Inhibrx Biosciences from a "sell" rating to a "hold" rating in a report on Sunday, August 17th. One analyst has rated the stock with a Hold rating, According to MarketBeat, the stock currently has an average rating of "Hold".

Inhibrx Biosciences Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.